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  Base	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  Body	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Celebra4ng	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Walter	  Frank	  Raphael	  Weldon	  
Vs.	  	  
William	  Bateson	  
Forthcoming	  by	  Greg	  Radick.	  Scholarly	  edi$on	  of	  W.	  F.	  R.	  Weldon's	  Theory	  of	  
Inheritance	  (1904-­‐1905),	  coedited	  with	  Anne	  Jamieson.	  
	  
Mendel’s laws of alternative inheritance in peas 29 
ESP FO U N D A T IO N S  SE R IE S  
PLATES. 
 
 
Plate I. 
 
 
 
 
Plate II. 
 
 
 
 
 
 
MENDEL’S LAWS  
OF  
ALTERNATIVE INHERITANCE IN PEAS. 
W. F.  R.  WELD O N 
 
 
 
 
 
 
 
 
 
Weldon, W. F. R. 1902. Mendel’s laws of alternative 
inheritance in peas. Biometrika, 1:228-254. 
 
 
 
 
 
 
 
 
 
! " # $
Complexity	  
•  There	  are	  ~25-­‐100	  TRILLION	  cells	  in	  each	  
human	  body,	  with	  ~6	  billion	  nucleo$des	  per	  
cell.	  
•  There	  is	  extensive	  modiﬁca$on	  of	  DNA,	  RNA	  
and	  proteins	  both	  spa$ally	  and	  temporally.	  
•  There	  are	  higher	  level	  mechanisms	  of	  soma$c	  
mosaicism,	  heterosis,	  and	  likely	  ancestral	  
inheritance.	  
Source:	  h@p://www.thenakedscien4sts.com/HTML/features/ar4cle/jamilcolumn1.htm/	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Abstract
Most human pre-mRNAs are spliced into linear molecules that retain the exon order defined by the genomic sequence. By
deep sequencing of RNA from a variety of normal and malignant human cells, we found RNA transcripts from many human
genes in which the exons were arranged in a non-canonical order. Statistical estimates and biochemical assays provided
strong evidence that a substantial fraction of the spliced transcripts from hundreds of genes are circular RNAs. Our results
suggest that a non-canonical mode of RNA splicing, resulting in a circular RNA isoform, is a general feature of the gene
expression program in human cells.
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Introduction
Deep sequencing of RNA from biological samples, ‘‘RNA-Seq’’,
is a powerful tool for discovering and cataloguing novel alterations
in the expression, sequence, and structure of transcriptomes. In the
present study, we used RNA-Seq in a deliberate search for
transcripts that could not be accounted for by conventional
splicing of primary transcripts from an unrearranged human
genome. Although our initial goal was to discover cancer-specific
chromosomal rearrangements by identifying the resulting fused or
rearranged transcripts, we also investigated the possibility that the
exon order specified by the genome sequence might be rearranged
during RNA processing. We were surprised to find numerous
examples of transcripts in which the exon order was a circular
permutation of the order encoded in the genome. We hypothe-
sized that these anomalous transcripts might the result of
intramolecular but non-canonical splicing events that joined a
splice donor to an upstream (i.e. toward the 59 end of the
transcript) splice acceptor to produce a circular RNA molecule.
Indeed, for many genes, in both cancer and normal human cells,
we found RNAs with circularly permuted exon orders at levels
comparable to those of the canonical, linear mRNA.
The first observation suggesting that eukaryotic RNAs can exist
in circular form was made more than 30 years ago by electron
microscopy [1]. 10 years later, human cytoplasmic RNA was
reported to contain very low levels of transcripts of the DCC gene
with exons spliced in non-canonical order (i.e. shuffled relative to
the reference genome). These scrambled transcripts were estimat-
ed to comprise less than one one-thousandth of DCC transcripts,
and the phenomenon was dubbed exon-scrambling [2]. Since that
time, a handful of expressed mammalian genes have been shown
to express circular RNA isoforms at low levels [3,4]. Such
examples include very low levels of human RNA transcripts with
scrambled exons observed in several human genes, including MLL
and ETS-1 [13,14].
The best-characterized circular transcripts are in rodents. The
mouse SRY gene, the sex-determining gene in males, consists of a
single exon. During development, the RNA exists as a linear
transcript that is translated into protein. In the adult testes, the
RNA exists primarily as a circular product that is predominantly
localized to the cytoplasm and is apparently not translated [5,6].
Studies have demonstrated that inverted repeats in the genomic
sequence flanking the SRY exon direct transcript circularization
[5,7,8]. The sodium transporter NCX1 and the rat cytochrome
P450 2C24 gene are two other well-studied examples of mouse
transcripts with circular isoforms that are expressed at relatively
low levels [9–11]. The circular isoform of the NCX1 gene is
thought to encode a protein, although this possibility has not been
conclusively demonstrated. Examples of exon scrambling have
also been found in Drosophila [12].
All examples of circular transcripts reported to date in humans
have been found to be expressed at low levels compared to the
dominant canonical linear isoform, requiring sensitive nested PCR
experiments for detection; these examples were discovered
inadvertently or in an effort to characterize the structure of
oncogenes. Circular RNAs have also been reported to be rare
isoforms of the human Cytochrome P-450 2C18, and dystrophin
transcripts [11,15]. Most recently, a circular isoform of the non-
coding RNA ANRIL was found to be expressed at very low levels;
its expression was correlated with INK4/ARF expression, and
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The	  Story	  began	  for	  me	  around	  1993,	  at	  ~age	  19….	  
	  
when	  I	  joined	  the	  lab	  of	  Don	  St.Germain	  to	  study	  
the	  role	  of	  thyroid	  hormone	  in	  cre4nism,	  which	  is	  
caused	  by	  lack	  of	  iodine	  during	  maternal	  
pregnancy,	  so	  this	  is	  an	  environmentally	  triggered	  
disease.	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Thyroid	  Hormone	  
Down	  Syndrome	  
Velocardiofacial	  (22q11.2)	  Syndrome	  
16p11.2	  dele$on,	  not	  in	  mother	  or	  
father,	  only	  in	  child.	  	  
5	  years	  old,	  but	  developmental	  age	  of	  2	  year	  old.	  
Speaks	  a	  few	  words,	  almost	  unintelligible.	  
Very	  hyperac$ve.	  
Can	  be	  withdrawn	  and	  has	  at	  $mes	  been	  diagnosed	  with	  “au$sm”.	  
Discovering	  a	  new	  syndrome	  and	  its	  
gene$c	  basis.	  
Ogden	  Syndrome	  
We	  found	  the	  SAME	  muta$on	  in	  two	  unrelated	  families,	  with	  a	  very	  similar	  
phenotype	  in	  both	  families,	  helping	  prove	  that	  this	  genotype	  contributes	  to	  the	  
phenotype	  observed.	  
First	  boy.	  Called	  “a	  lihle	  old	  man”	  by	  
the	  family.	  Died	  around	  ~1	  year	  of	  
age,	  from	  cardiac	  arrhythmias.	  
This	  is	  the	  ﬁrst	  boy	  in	  the	  late	  1970’s.	  
prominence	  of	  eyes,	  down-­‐sloping	  palpebral	  ﬁssures,	  thickened	  
eyelids,	  large	  ears,	  beaking	  of	  nose,	  ﬂared	  nares,	  hypoplas$c	  nasal	  
alae,	  short	  columella,	  protruding	  upper	  lip,	  micro-­‐retrognathia	  
	  
This	  is	  the	  “Proband”	  photograph	  presented	  at	  Case	  Conference.	  
II-1 III-2 
A	  
B	  
C	   D	  
II-­‐1	   II-­‐6	   III-­‐7	  III-­‐4	   III-­‐6	  
These	  are	  the	  Major	  Features	  of	  the	  Syndrome.	  
“ground	  truth”	  Genome	  from	  blood	  of	  one	  person	  
	  (of	  course,	  that	  is	  from	  millions	  of	  cells	  and	  only	  blood,	  	  
not	  other	  $ssues)	  
	  
~3	  billion	  nucleo$des	  
True	  nega$ve	  
True	  posi$ve	  	  
“exon	  capture	  and	  sequencing”	  
	  
Exon	  =	  set	  of	  con$guous	  nucleo$des	  
predicted	  to	  contribute	  toward	  a	  protein	  
“Exome”	  
!  We	  performed	  X-­‐chromosome	  exon	  capture	  
with	  Agilent,	  followed	  by	  Next	  Gen	  
Sequencing	  with	  Illumina.	  
!  We	  analyzed	  the	  data	  with	  ANNOVAR	  and	  
VAAST	  (Variant	  Annota4on,	  Analysis	  and	  
Search	  Tool).	  New	  computa4onal	  tools	  for	  
iden4fying	  disease-­‐causing	  muta4ons	  by	  
individual	  genome	  sequencing.	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VAAST	  integrates	  AAS	  &	  Variant	  frequencies	  
in	  a	  single	  probabilis4c	  framework	  	  
 
•   non-coding variants scored using allele frequency differences 
•  ni : frequency of variant type among all variants observed in 
Background and Target genomes 
 
•  ai: frequency of variant type among disease causing mutations in 
OMIM 
•  This approach means that every variant can be scored, non-synonymous,   
  synonymous, coding, and non-coding. Phylogenetic conservation not     
  required. 

Mutation 
WT 
C C C 
Pro37 
Proband  
Unaffected 
Brother 
C T T G G	  T C T C 
Ser37 
C 
T 
This is the mutation we found… one nucleotide change 
out of 6 billion nucleotides in a diploid genome… 
Iden$ty	  by	  Descent	  Analysis	  shows	  
that	  the	  muta$on	  must	  have	  arisen	  
independently	  in	  two	  diﬀerent	  
families.	  
Courtesy	  of	  Chad	  Huﬀ	  and	  Lynn	  Jorde	  
"This	  exempliﬁes	  an	  excep$onally	  
rare	  disease,	  but	  the	  same	  type	  
of	  strategy	  is	  now	  going	  to	  be	  
applied	  to	  more	  common	  
diseases	  to	  get	  the	  root	  cause,"	  
says	  Eric	  Topol,	  a	  medical	  
gene$cist	  at	  the	  Scripps	  Research	  
Ins$tute	  in	  La	  Jolla,	  California.	  
	  
"This	  is	  one	  of	  the	  most	  exci$ng	  
things	  in	  medicine,"	  says	  Topol.	  
"We're	  going	  to	  take	  the	  term	  
'idiopathic'	  which,	  basically	  
means	  'we	  don't'	  know,'	  and	  
eliminate	  it."	  
A	  prisoner	  at	  Dartmoor	  is	  forced	  to	  turn	  a	  crank	  handle	  repeatedly	  as	  a	  form	  of	  
punishment,	  as	  depicted	  in	  an	  illustra$on	  dated	  1884.	  
Once	  one	  ﬁnds	  a	  validated	  high-­‐eﬀect	  
size	  muta$on,	  func$onal	  analysis	  is	  
appropriate.	  
S39 mutation? 
growth defect of 
“humanized” strains 
growth defect at 39°C 
ribosome defect? 
no difference cyclo/doxo? 
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Gene	   Length	   Gene	   Length	   Iden4ty	  Score	  %	  
human	   235	   vs	   c_elegans	   181	   68	  
human	   235	   vs	   s_pombe	   177	   57	  
human	   235	   vs	   s_cerevisiae	   238	   38	  
c_elegans	   181	   vs	   s_pombe	   177	   57	  
c_elegans	   181	   vs	   s_cerevisiae	   238	   48	  
s_pombe	   177	   vs	   s_cerevisiae	   238	   52	  
Sequences	  were	  aligned	  using	  Clustal	  mul$ple	  sequence	  alignment	  tool.	  The	  
Scores	  Table	  shows	  the	  pairwise	  scores	  calculated	  for	  every	  pair	  of	  sequences	  
that	  is	  to	  be	  aligned.	  Pairwise	  scores	  are	  simply	  the	  number	  of	  iden$$es	  
between	  the	  two	  sequences,	  divided	  by	  the	  length	  of	  the	  alignment,	  and	  
represented	  as	  a	  percentage.	  This	  alignment	  is	  only	  a	  precursor	  to	  the	  full	  
mul$ple	  alignment	  and	  might	  not	  be	  preserved.	  
NAA10	  Alignments	  
CLUSTAL 2.1 multiple sequence alignment 
  
h_sapiens_V1      --MNIRNARPEDLMNMQHCNLLCLPENYQMKYYFYHGLSWPQLSYIAE------------ 46 
c_elegans         --MNIRCARVDDLMSMQNANLMCLPENYQMKYYFYHALSWPQLSYIAE------------ 46 
s_pombe           --MDIRPARISDLTGMQNCNLHNLPENYQLKYYLYHAISWPMLSYVAT------------ 46 
s_cerevisiae      MPINIRRATINDIICMQNANLHNLPENYMMKYYMYHILSWPEASFVATTTTLDCEDSDEQ 60 
                    ::** *  .*:  **:.**  ***** :***:** :***  *::*              
  
h_sapiens_V1      DENG--------------------------KIVGYVLAKMEEDPDD---VPHGHITSLAV 77 
c_elegans         DHKG--------------------------NVVGYVLAKMEEDPGE---EPHGHITSLAV 77 
s_pombe           DPKG--------------------------RVVGYVLAKMEEEPKDG--IPHGHITSVSV 78 
s_cerevisiae      DENDKLELTLDGTNDGRTIKLDPTYLAPGEKLVGYVLVKMNDDPDQQNEPPNGHITSLSV 120 
                  * :.                          .:*****.**:::* :    *:*****::* 
  
h_sapiens_V1      KRSHRRLGLAQKLMDQASRAMIENFNAKYVSLHVRKSNRAALHLYSNTLNFQISEVEPKY 137 
c_elegans         KRSYRRLGLANKMMDQTARAMVETYNAKYVSLHVRVSNRAALN-YKNTLKFEIVDTEPKY 136 
s_pombe           MRSYRHLGLAKRLMVQSQRAMVEVYGAKYMSLHVRKSNRAAIHLYRDTLQFDVQGIESKY 138 
s_cerevisiae      MRTYRRMGIAENLMRQALFALREVHQAEYVSLHVRQSNRAALHLYRDTLAFEVLSIEKSY 180 
                   *::*::* :*:.:* *:  *: * . *:*:***** *****:: * :** *::   * .* 
  
h_sapiens_V1      YADGEDAYAMKR--DLTQMADELRRHLELKEKGRHVVLGAIENKVESKGNSPPSSGEACR 195 
c_elegans         YADGEDAYAMRR--DLAKWAEE--RNIEPADR---------------------------- 164 
s_pombe           YADGEDAYAMHK--DFSTLKFD---TPETN------------------------------ 163 
s_cerevisiae      YQDGEDAYAMKKVLKLEELQISNFTHRRLKENE--------------------------- 213 
                  * ********::  .:     .     .                                 
  
h_sapiens_V1      EEKGLAAEDSGGDSKDLSEVSETTESTDVKDSSEASDSAS-- 235 
c_elegans         ------------------EAYTTAKTTDDKKKNRS------- 181 
s_pombe           -----------------DELAKTVQSLALNN----------- 177 
s_cerevisiae      -----------------EKLEDDLESDLLEDIIKQGVNDIIV 238 
                                    :     ::   :.            
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yeast growth 
This is with plasmid over-expressing the 
various proteins. A 5 ml overnight culture was 
grown in SD-URA at 30°C. Cells were diluted to 
an OD600 of 0.1 and either spotted in 1:5 
serial dilutions on plates for 48 h (upper 
panel) or grown in 2 ml cultures at 30°C or 
39°C under constant agitation for 24 h (lower 
panel). Optical density was plotted. 
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yeast growth 
A 5 ml overnight culture was grown in SD-URA 
at 30°C. Cells were diluted to an OD600 of 0.1 
and either spotted in 1:5 serial dilutions on 
plates for 48 h (upper panel) or grown in 2 ml 
cultures at 30°C or 39°C under constant 
agitation for 24 h (lower panel). Optical 
density was plotted. 
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Endogenous, single-copy genes in yeast. 
 
yeast growth 
A 5 ml overnight culture was grown in SD-
URA at 30°C. Cells were diluted to an OD600 
of 0.1 and either spotted in 1:5 serial 
dilutions on plates for 48 h (upper panel) or 
grown in 2 ml cultures at 30°C or 39°C 
under constant agitation for 24 h (lower 
panel). Optical density was normalized to 
the W303 wt strain for every independent 
experiment and plotted (X). The median of 
all experiments is shown as a short line 
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Remarkably:	  
•  We	  do	  not	  really	  know	  the	  expression	  of	  
prehy	  much	  ALL	  muta$ons	  in	  humans,	  as	  we	  
have	  not	  systema$cally	  sequenced	  or	  
karyotyped	  any	  gene$c	  altera$on	  in	  
Thousands	  to	  Millions	  of	  randomly	  selected	  
people.	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Medical genetics typically entails the detailed characterization of a patient’s phenotypes followed
by genotyping to discover the responsible gene or mutation. Here, we propose that the systematic
discovery of genetic variants associatedwith complex diseases such as autism are progressing to a
point where a reverse strategy may be fruitful in assigning the pathogenic effects of many different
genes and in determining whether particular genotypes manifest as clinically recognizable pheno-
types. This ‘‘genotype-first’’ approach for complex disease necessitates the development of large,
highly integrated networks of researchers, clinicians, and patient families, with the promise of
improved therapies for subsets of patients.
The genetic study of complex disease has
historically been difficult, meeting with
limited success and often even fewer
therapeutic advances in patient care. Un-
like Mendelian disorders, complex dis-
ease is defined as a phenotype that is
not caused by a single gene mutation
but, rather, by many individual gene
events, with a significant contribution
from environmental factors. The nature
of complex genetic diseasemakes patient
care difficult, as a clinician may never see
two individuals with the same gene muta-
tion and, therefore, the same underlying
genetic etiology. Classical approaches
to the study of complex disease have
identified patientswith similar phenotypes
and have attempted to identify the com-
mon causative mutation for this pheno-
type using association studies. Though
there have been numerous loci reported
over the last 10 years, in most cases,
much of the heritability of complex dis-
ease remains unresolved (Manolio et al.,
2009). The number of success stories
for complex neurocognitive and neuro-
behavioral disease are even fewer, with
enormous numbers of patients (>30,000)
being required to discover a small fraction
of the genetic risk using genome-wide
association study (GWAS) approaches
(McCarroll and Hyman, 2013). Complex
neurodevelopmental disorders, such as
autism, schizophrenia, bipolar disorder,
intellectual disability (ID), and devel-
opmental delay (DD), require better
approaches to link genotype to pheno-
type. In this Essay, we focus on autism
spectrum disorder (ASD)—a highly com-
plex neurodevelopmental disease with a
range of phenotypes and a large patient
base—and propose a gene-centric meth-
odology to model a streamlined approach
for subtyping autism starting with the
genotype (Schulze and McMahon, 2004).
The explosion of data from recent
exome studies (Iossifov et al., 2012; Neale
et al., 2012; O’Roak et al., 2012b; Sanders
et al., 2012) and earlier work on large copy
number variants (CNVs) (de Vries et al.,
2005; Sebat et al., 2007; Sharp et al.,
2006) have emphasized the importance
of sporadic truncating mutations in ASD,
revealing a surprising level of genetic het-
erogeneity among patients. From these
data, it has been estimated that >500
distinct loci may be related to disease
etiology in ASD, assuming a model of
sporadic protein-encoding mutations.
Interestingly, more than two decades
ago, Percy postulated that a ‘‘very wide
variety of autistic syndromes depending
on underlying etiology’’ may exist based
on his observation that a significant frac-
tion of individuals with fragile X, Rett,
and tuberous sclerosis syndromes could
be classified as having autistic features
(Percy et al., 1990). Whereas traditional
genetics approaches were entirely under-
powered to detect small subpopulations
of autism with a common mutant gene,
the advent of next-generation sequencing
technology has made it possible to begin
to systematically classify genetic sub-
types of ASD and, further, to ask whether
these define specific clinical subtypes of
ASD. For the purpose of this Essay, we
will define a ‘‘genetic subtype’’ as a gene
in which recurrent mutations show an
excess of burden in patients versus con-
trols. This is distinguished from a ‘‘molec-
ular subtype’’ that constitutes a group of
genetic subtypes that are linked together
in a common pathway (coexpression,
protein-protein interaction network, etc.)
(O’Roak et al., 2012b).
The extreme genetic heterogeneity
exemplified by autism, we believe, re-
quires a shift in the approach to studying
the genetics of complex neurological
disease. Instead of comprehensive and
exhaustive phenotyping as the first step
to reducing genetic heterogeneity, we
propose to leverage technology to genet-
ically classify subtypes of disease among
patients in whom clinical recontact is
possible. We outline three logical steps
in characterizing genetic subtypes from
the perspective of autism: (1) candidate
discovery and determination of pathoge-
nicity, (2) comprehensive clinical pheno-
typing, and (3) resolution of genetic
872 Cell 156, February 27, 2014 ª2014 Elsevier Inc.
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random mutation modeling40 to calculate the likelihood that observed 
(de novo) mutations have a damaging effect. Similar prioritizations 
are provided by tools that score individual mutation severity (SIFT, 
PolyPhen2, MutationTaster, MutPred, CONDEL, etc.), some of which 
can be adapted to a gene-based prioritization score from genome-wide 
data41. These population data provide a powerful unbiased approach 
to home in on genes that are likely to be among the most penetrant 
because of the complete absence of disruptive variation in the general 
population (for example, CHD8 or DYRK1A). A critical aspect of such 
analyses is the reliability of a particular gene model. Most human 
genes show evidence of alternative splice forms, many of which have 
no known function. Apparent hotspots of mutation for a particular 
exon (often exon-intron boundaries) in both cases and controls may 
suggest misannotation, the presence of a processed pseudogene or an 
alternative, nonfunctional splice form.
Pathway enrichment and links to cancer biology
Another popular approach to discern the most important gene 
candidates for further disease association and characterization has 
been to identify specific biological networks of genes enriched in 
cases as compared to controls. Although this approach cannot be used 
unequivocally to define causality, membership of a specific gene in a 
particular protein-protein interaction (PPI) or coexpression network 
may increase the likelihood of its association with disease. Numerous 
studies have reported significant enrichment of both de novo 
CNV and single-nucleotide variant (SNV) mutations in particular 
pathways3,4,42,43. O’Roak et al.3, for example, reported a significant 
enrichment of de novo disruptive autism mutations among proteins 
associated with chromatin remodeling and ?-catenin and WNT 
signaling—a finding that was replicated in a follow-up resequencing 
study of more than 2,400 probands. One recent instance, in which 
membership of a new candidate gene in a PPI network led to the 
discovery of an autism-associated gene, is ADNP. A single ADNP 
LoF mutation was initially observed in exome sequencing studies. 
Although the observed mutation frequency in this gene did not reach 
statistical significance when cases and controls were compared20, 
it was strongly implicated in the PPI network originally defined 
by O’Roak et al.3 Targeted resequencing experiments combined 
with clinical exome sequencing identified several more cases with 
de novo mutations and remarkably similar phenotypes represent-
ing a new SWI-SNF–related autism syndrome (Fig. 3)44. Notably, 
many of the genes implicated in the ?-catenin pathway have also been 
described as mutated in patients with ID1 but not in patients with 
SCZ. Similarly, an enrichment of genes interacting with FMR1 (also 
known as FMRP)—the gene responsible for fragile X syndrome—has 
been reported with de novo mutations in ASD5, epilepsy11 and, most 
recently, SCZ10,45. Whether this observation is due to the relative high 
incidence of cases that also presented with comorbid ID remains to 
be determined.
In addition to PPI networks, studies of coexpression have shown 
enrichment for specific spatio-temporal patterns of expression. 
A study of coexpressed genes affected by de novo mutations reported 
an enrichment in fetal prefrontal cortical network in SCZ8, which is 
in line with the finding by Xu et al.9 that genes with higher expression 
Table 4 Recurrent identical de novo mutations in 6 genes identified in 11 exome studies with different neurodevelopmental phenotypes
Gene Coding effect Mutation (genomic DNA level) Mutation (cDNA level)
Mutation  
(protein level) Study Disorder
ALG13 Missense ChrX(GRCh37):g.110928268A>G NM_001099922.2:c.320A>G p.Asn107Ser de Ligt et al.1 ID
ALG13 Missense ChrX(GRCh37):g.110928268A>G NM_001099922.2:c.320A>G p.Asn107Ser Allen et al.11 EE
ALG13 Missense ChrX(GRCh37):g.110928268A>G NM_001099922.2:c.320A>G p.Asn107Ser Allen et al.11 EE
KCNQ3 Missense Chr8(GRCh37):g.133192493G>A NM_001204824.1:c.328C>T p.Arg110Cys Rauch et al.2 ID
KCNQ3 Missense Chr8(GRCh37):g.133192493G>A NM_001204824.1:c.328C>T p.Arg110Cys Allen et al.11 EE
SCN1A Splice donor LRG_8:g.24003G>A NM_006920.4:c.602+1G>A p.? Allen et al.11 EE
SCN1A Splice donor LRG_8:g.24003G>A NM_006920.4:c.602+1G>A p.? Allen et al.11 EE
CUX2 Missense Chr12(GRCh37):g.111748354G>A NM_015267.3:c.1768G>A p.Glu590Lys Rauch et al.2 ID
CUX2 Missense Chr12(GRCh37):g.111748354G>A NM_015267.3:c.1768G>A p.Glu590Lys Allen et al.11 EE
SCN2A Missense Chr2(GRCh37):g.166198975G>A NM_021007.2:c.2558G>A p.Arg853Gln Allen et al.11 EE
SCN2A Missense Chr2(GRCh37):g.166198975G>A NM_021007.2:c.2558G>A p.Arg853Gln Allen et al.11 EE
DUSP15 Missense Chr20(GRCh37):g.30450489G>A NM_080611.2:c.320C>T p.Thr107Met Neale et al.7 ASD
DUSP15 Missense Chr20(GRCh37):g.30450489G>A NM_080611.2:c.320C>T p.Thr107Met Fromer et al.10 SCZ
EE, epileptic encephalopathies; ASD, autism spectrum disorder; ID, intellectual disability; SCZ, schizophrenia.
Figure 1 Genes with recurrent de novo mutations in four 
neurodevelopmental disorders. (a) We estimate the number of fully penetrant 
genes that can explain disease once mutated, based on a de novo model 
using the ‘unseen species problem’. We consider all recurrent missense or 
LoF de novo mutations pathogenic, as well as a defined fraction of mutations 
in genes observed just once (because it is unlikely that all de novo mutations 
are pathogenic). The ratio between genes mutated recurrently and the rate 
of singleton mutations suggests an estimate for the true number of genes 
pathogenic when mutated. Including more singleton mutations increases 
the fraction of each disorder explained by single de novo SNVs at the cost 
of including more genes as pathogenic. Initial exome sequencing studies of 
epilepsy and ID focused on specific pediatric subtypes or the most severe 
cases; thus, the number of generalized epilepsy- or ID-associated genes is 
likely to be much higher. EE, epileptic encephalopathies; ASD, autism spectrum disorder; ID, intellectual disability; SCZ, schizophrenia. (b) Expected  
hit rate (or sensitivity) of true positive genes discovered using trio sequencing studies (under a family-wise error rate of 5%; that is, each gene passes exome-
wide significance of 2.6 × 10−6). We estimate the power of trio sequencing to detect statistically significant associations for disease-associated genes,  
under the assumption that 10% or 20% of singleton mutations could be fully penetrant (vertical bars in a). We assume the distribution of these genes is 
uniform within each disorder and that they do not differ significantly from all genes in terms of length and mutability, although these are taken into account 
when determining significance.
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Recent exome (and genome) sequencing studies of families have aimed 
to comprehensively discover genetic variation to identify the most 
likely causal mutation in patients with disease. Sequencing studies of 
parent-proband trios for probands with intellectual disability (ID)1,2, 
autism spectrum disorder (ASD)3–7, schizophrenia (SCZ)8–10 and epi-
lepsy11 have all suggested that de novo point mutations are important 
in pediatric and adult disorders of brain development (Table 1). The 
relative contribution of de novo mutations to each disorder remains to 
be determined but appears to correlate well with the degree of reduced 
fitness or fecundity of the given condition12. However, not only 
de novo events but also rare inherited copy number variants (CNVs) 
can have an effect on fecundity, though their overall effect on fecundity 
is still debated13. Biologically, 75–80% of de novo point mutations arise 
paternally3,14, likely as a result of the greater number of cell divisions 
in the male germline lineage than in the female lineage. These findings 
are consistent with some epidemiological data that find advancing 
paternal age to be a significant predictor of ASD, ID and SCZ15–17 and 
argue for the need to properly control for paternal age when comparing 
mutation rates between probands and siblings. The importance of 
de novo and private rare mutations is especially important clinically, 
as there are now reports of diagnostic yields ranging from 10–55%  
for select (usually the most severe) groups of patients with ID1,2 and 
epilepsy18, in addition to resolution of unsolved Mendelian disorders19. 
It is clear that next-generation sequencing approaches have provided 
powerful tools for identifying genes harboring potentially pathogenic 
mutations. Deciding which genes to pursue, however, is not always 
self-evident because follow-up research and diagnostic studies are 
critical to understanding the full contribution of a particular mutation 
to its respective phenotype.
In this Review, we will discuss the prioritization of candidate genes 
identified through sequencing studies, show emerging trends and 
highlight potential strategies for subsequent functional characteriza-
tion of these neurodevelopmental genes. We focus on lessons learned 
from 11 recent studies that report 2,368 de novo mutations from a 
total of 2,358 probands and 600 de novo mutations from 731 controls 
(Table 1). The bulk of the data originate from sequencing studies 
of parents and probands with ASD, ID and epileptic encephalopa-
thies, but more recent studies have also highlighted the importance of 
de novo mutations in SCZ. There is evidence that de novo mutations, 
particularly disruptive mutations, occur in the same genes despite the 
nosological distinction for these different diseases. For the purpose of 
this Review, we collectively term these diseases ‘neurodevelopmental 
disorders’ but recognize that some, especially adult-onset diseases 
such as SCZ, may have etiologic components that are not neurode-
velopmental in origin.
Recurrently mutated genes
One of the frequently used concepts in considering possible ‘new 
disease genes’ responsible for a given neurodevelopmental pheno-
type is the recurrence of de novo mutations in the same gene, along 
with the absence of such mutations in healthy controls. This rule 
follows the precedent established for the discovery of pathogenic 
de novo CNVs during the last decade, with the highest priority 
given to recurrent mutations that lead to a complete loss of func-
tion of one of the parental copies of the gene. Up to ten independ-
ent reports of de novo mutations in SCN2A and nine independent 
reports of de novo mutations in SCN1A and STXBP1 have been 
described (Tables 2 and 3). Strikingly, de novo mutations in those 
genes have so far been found exclusively in probands and never in 
controls. Simulation data suggest that at least two but certainly three 
or more recurrent de novo loss-of-function (LoF) events (that is, 
predicted nonsense, frameshift or canonical splice site mutations) 
1Department of Human Genetics, Radboud Institute for Medical Life Sciences, 
Radboud University Medical Center, Nijmegen, The Netherlands. 2Department of 
Genome Sciences, University of Washington, Seattle, Washington, USA. 3Howard 
Hughes Medical Institute, University of Washington, Seattle, Washington, USA. 
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Prioritization of ne rodevelopmental disease 
genes by discovery of new mut tions
Alexande  Hoischen1, Niklas Krumm2 & Evan E Eichler2,3
Advances in genome sequencing technologies have begun to revolutionize neurogenetics, allowing the full spectrum of genetic 
variation to be better understood in relation to disease. Exome sequencing of hundreds to thousands of samples from patients 
with autism spectrum disorder, intellectual disability, epilepsy and schizophrenia provides strong evidence of the importance of 
de novo and gene-disruptive events. There are now several hundred new candidate genes and targeted resequencing technologies 
that allow screening of dozens f genes in tens of thousa ds of individuals with h gh specificity and sensitivity. The de ision 
of which genes to pursue depends on many factors, including recurrence, previous evidence of overlap with pathogenic copy 
number variants, the position of the mutation in the protein, the mutational burden among healthy individuals and membership 
of the candidate gene in disease-implicated protein networks. We discuss these emerging criteria for gene prioritization and the 
potential impact on the field of neuroscience.
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in early fetal life have substantial contribu-
tion to SCZ by de novo mutations. Similarly, 
Willsey et al.46 working with a few high- 
confidence sets of ASD-associated genes as 
seeds reported a convergence of the expres-
sion of these genes in deep-layer cortical 
projection neurons (layers 5 and 6) in mid-
fetal development. Another analysis using a 
larger set of ASD and ID risk genes suggested translational regulation 
by FMR1 and an enrichment in superficial cortical layers43. Implicit 
in these types of analyses is the notion that, while more than 1,000 
genes may be responsible for ASD or ID, in the end the genes will con-
verge on a few highly enriched networks of related genes. It is possible 
that molecular therapies targeted to the network at a specific stage of 
development, as opposed to the individual gene, may be beneficial to 
specific groups of patients.
Related to this, it is intriguing that several recurring genes and 
pathways that have been implicated in neurodevelopmental disease 
have also been associated with different forms of cancer (Fig. 4)47. 
While clear-cut examples such as the mutation of the tumor sup-
pressor genes PTEN (Cowden syndrome) or ARID1B (Coffin-Siris 
syndrome) in neurodevelopmental disease have been extensively 
reviewed48, more recent exome sequencing data from patients with 
neurodevelopmental disease suggest new links. The most striking 
observation here is the identical point mutations reported to cause 
cancer when mutated somatically and severe neurodevelopmental syn-
dromes when mutated in the germline. Examples include the identical 
mutations in SETBP1 (ref. 32), ASXL1 (ref. 49) and EZH2 (ref. 50), as 
well as several genes of the RAS–MAP kinase pathway associated with 
parental-age-effect Mendelian disorders51 (Supplementary Table 1). 
It is important to stress that this is an observation at an individual 
gene level and should not be translated to an epidemiological link: 
that is, this cannot be generalized to speculate that patients with neuro-
developmental disorders in these specific genes will all be at a higher 
risk for certain cancer types. Instead, it is likely that this convergence 
represents a selection of genes that are fundamental to cell biology 
(for example, cell proliferation and/or membership in multi-subunit 
complexes associated with chromatin remodeling). There is also the 
distinct possibility of pleiotropy; that is, the genes and pathways have 
completely unrelated functions, explaining developmental defects and 
cancer independently. Therefore, de novo mutations in those genes 
can result in different outcomes depending on timing, genetic back-
ground and cellular context. Nevertheless, there may be advantages 
to integrating sequence data from patients with neurodevelopmental 
disease and massive sequencing programs devoted to the discovery of 
somatic mutations in tumors—for example, the International Cancer 
Genome Project52. It is possible that these intersections will help to 
further prioritize genes important in both cellular development and 
neurodevelopment.
Phenotypic similarity of recurrent de novo mutations
Although essential, statistical support of recurrent mutations is 
not the sole arbiter in determining pathogenicity of particular 
mutations and genes. In particular, it is important to consider the 
phenotypic presentation and overlap of the individuals with the same 
presumptive underlying genetic lesion. In this regard, we note that 
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Figure 2 CNV and exome intersections define 
candidate genes. (a,b) Deletion (red) and 
duplication (blue) burden for developmental 
delay or ID cases and controls for two genes, 
DYRK1A (a) and MBD5 (b), as compared to 
sporadic LoF mutations on the basis of exome 
sequencing of 209 autism simplex trios. DYRK1A 
is a strong candidate gene for cognitive deficits 
associated with Down syndrome; LoF mutations 
are associated with minibrain phenotype in 
Drosophila65, autism-like behavior in mouse64 
and a deletion syndrome in humans27,63. MBD5 
has been implicated as the causal gene for 
the 2q23.1 deletion syndrome associated with 
epilepsy, autism and ID91,92.
a bFigure 3 Phenotypic similarity of two patients 
with identical PACS1 de novo mutations and two 
patients with similar ADNP mutations. (a) These 
two unrelated patients show identical de novo 
point mutations (c.607C>T; p.Arg203Trp) in 
PACS1 (RefSeq NM_018026.3)53. The striking 
similarity in phenotype includes low anterior 
hairline, highly arched eyebrows, synophrys, 
hypertelorism with downslanted palpebral 
fissures, long eyelashes, a bulbous nasal tip, a 
flat philtrum with a thin upper lip, downturned 
corners of the mouth and low-set ears. Reprinted 
from ref. 53, Copyright (2012), with permission from The American Society of Human Genetics. (b) These two unrelated patients both show LoF mutations 
in ADNP (c.2496_2499delTAAA; p.Asp832Lysfs*80 and c.2157C>G; p.Tyr719*)44 resulting in a new SWI-SNF–related autism syndrome. Patients present 
with clinical similarities, including a prominent forehead, a thin upper lip and a broad nasal bridge. Reprinted from ref. 44.
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Abstract
To identify previously reported disease mutations that are compatible with
extraordinary longevity, we screened the coding regions of the genomes of 44
Ashkenazi Jewish centenarians. Individual genome sequences were generated
with 309 coverage on the Illumina HiSeq 2000 and single-nucleotide variants
were called with the genome analysis toolkit (GATK). We identified 130 coding
variants that were annotated as “pathogenic” or “likely pathogenic” based on
the ClinVar database and that are infrequent in the general population. These
variants were previously reported to cause a wide range of degenerative, neo-
plastic, and cardiac diseases with autosomal dominant, autosomal recessive, and
X-linked inheritance. Several of these variants are located in genes that harbor
actionable incidental findings, according to the recommendations of the Ameri-
can College of Medical Genetics. In addition, we found risk variants for late-
onset neurodegenerative diseases, such as the APOE e4 allele that was even
present in a homozygous state in one centenarian who did not develop Alzhei-
mer’s disease. Our data demonstrate that the incidental finding of certain
reported disease variants in an individual genome may not preclude an extraor-
dinarily long life. When the observed variants are encountered in the context of
clinical sequencing, it is thus important to exercise caution in justifying clinical
decisions.
Introduction
Human genetic studies have linked many variants to
human diseases or nondisease phenotypes. How to handle
the incidental finding of a disease variant is a topic of
current discussion (Green et al. 2013a; Klitzman et al.
2013). Incidental findings often occur, when genome
sequencing data are screened for disease-causing variants
that are recorded in databases such as Online Mendelian
Inheritance in Man (OMIM) (Hamosh et al. 2005) or,
more recently, ClinVar (Landrum et al. 2014) and the
Genome Wide Association Studies (GWAS) catalog
ª 2014 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
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“Number	  of	  genes	  causing	  au$sm”	  
•  Exome	  sequencing	  on	  3000	  quad	  families,	  i.e.	  
mother,	  father,	  two	  children.	  
•  Looking	  for	  newly	  arising	  muta$on	  in	  child	  
with	  au$sm,	  not	  found	  in	  parents	  or	  
unaﬀected	  sibling.	  
•  Es$ma$ng	  ~500	  “genes”	  involved.	  
Researchers	  develop	  gene4c	  proﬁle	  of	  
the	  Netherlands	  
	  
•  “The	  Genome	  of	  the	  Netherlands	  can	  greatly	  
accelerate	  research	  into	  genes	  that	  play	  a	  key	  role	  
in	  the	  development	  of	  chronic	  and	  age-­‐related	  
diseases.	  We	  can	  now	  focus	  speciﬁcally	  on	  the	  
disease-­‐causing	  genes”.	  
•  “A	  no$ceable	  result	  is	  that	  every	  par$cipant	  in	  
this	  research	  on	  average	  turned	  out	  to	  have	  
twenty	  muta$ons	  that	  were	  thought	  to	  cause	  
rare	  diseases,	  although	  the	  par$cipants	  were	  
perfectly	  healthy”.	  
hhp://medicalxpress.com/news/2014-­‐06-­‐gene$c-­‐proﬁle-­‐netherlands.html	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“There	  are	  ~12	  billion	  nucleo$des	  in	  every	  cell	  of	  the	  human	  body,	  and	  there	  are	  
~25-­‐100	  trillion	  cells	  in	  each	  human	  body.	  Given	  soma$c	  mosaicism,	  epigene$c	  
changes	  and	  environmental	  diﬀerences,	  no	  two	  human	  beings	  are	  the	  same,	  
par$cularly	  as	  there	  are	  only	  ~7	  billion	  people	  on	  the	  planet”.	  	  
Categorical	  Thinking	  Misses	  Complexity	  

A	  conceptual	  model	  of	  genotype-­‐phenotype	  correla4ons.	  	  The	  y	  plane	  represents	  a	  
phenotypic	  spectrum,	  the	  x	  plane	  represents	  the	  canalized	  progression	  of	  development	  
through	  $me,	  and	  the	  z	  plane	  represents	  environmental	  ﬂuctua$ons.	  	  	  
Time	  
Environment	  
Phenotypic	  
Spectrum	  
E.	  coli	  adap$ng	  to	  low	  glucose	  condi$ons,	  in	  the	  context	  of	  media	  
containing	  citrate.	  –	  Richard	  Lemski	  experiment	  	  
Analy$c	  Validity	  
•  Sequencing	  “clinical-­‐grade	  genomes”	  
•  Bioinforma$cs	  analysis	  
	  
Clinical	  Validity	  
	  
•  Gene4c	  architecture	  of	  illness	  
Limits	  of	  our	  current	  technology	  &	  knowledge	  
	  

REPORT
XLID-Causing Mutations and Associated Genes Challenged
in Light of Data From Large-Scale Human Exome Sequencing
Ame´lie Piton,1,2,4,* Claire Redin,1,2,4 and Jean-Louis Mandel1,2,3,*
Because of the unbalanced sex ratio (1.3–1.4 to 1) observed in intellectual disability (ID) and the identification of large ID-affected fam-
ilies showing X-linked segregation, much attention has been focused on the genetics of X-linked ID (XLID). Mutations causing mono-
genic XLID have now been reported in over 100 genes, most of which are commonly included in XLID diagnostic gene panels. Nonethe-
less, the boundary between true mutations and rare non-disease-causing variants often remains elusive. The sequencing of a large
number of control X chromosomes, required for avoiding false-positive results, was not systematically possible in the past. Such infor-
mation is now available thanks to large-scale sequencing projects such as the National Heart, Lung, and Blood (NHLBI) Exome
Sequencing Project, which provides variation information on 10,563 X chromosomes from the general population. We used this NHLBI
cohort to systematically reassess the implication of 106 genes proposed to be involved in monogenic forms of XLID. We particularly
question the implication in XLID of ten of them (AGTR2, MAGT1, ZNF674, SRPX2, ATP6AP2, ARHGEF6, NXF5, ZCCHC12, ZNF41,
and ZNF81), in which truncating variants or previously published mutations are observed at a relatively high frequency within this
cohort. We also highlight 15 other genes (CCDC22, CLIC2, CNKSR2, FRMPD4, HCFC1, IGBP1, KIAA2022, KLF8, MAOA, NAA10,
NLGN3, RPL10, SHROOM4, ZDHHC15, and ZNF261) for which replication studies are warranted. We propose that similar reassessment
of reported mutations (and genes) with the use of data from large-scale human exome sequencing would be relevant for a wide range of
other genetic diseases.
Introduction
Intellectual disability (ID, formerly called mental retarda-
tion) is a developmental brain disorder commonly defined
by an IQ below 70 and limitations in both intellectual
functioning and adaptive behavior. ID can originate from
environmental causes and/or genetic anomalies, and its
incidence in children is estimated to be of 1%–2%.1,2 As
a result of an excess of males affected by ID (the male-to-
female ratio is 1.3–1.4 to 1) and the identification of
many families presenting with a clear X-linked segrega-
tion, much attention has been focused for the last 20 years
on genes located on the X chromosome and thus respon-
sible for X-linked ID (XLID, previously known as XLMR)
when mutated.3,4 One of the first genes identified as
involved in XLID is FMR1 (MIM 309550), a target of the
unstable expansion mutation responsible for fragile X syn-
drome (MIM 300624); accounting for about 1%–2% of all
ID cases, this mutation still remains the most common
cause of XLID.5,6 Since then, the number of genes involved
in XLID when mutated has grown exponentially,3,7,8 from
only 11 in 1992 to 43 in 2002 and over 100 genes now
identified thank to the efforts of various teams.4,9,10 Half
of the known genes carrying mutations responsible for
XLID appear to be associated with nonsyndromic or pauci-
syndromic forms; the other half are associated with more
syndromic forms (i.e., ID associated with defined clinical
or metabolic manifestations), which facilitates the identifi-
cation of causative mutations in the same gene because
unrelated probands with comparable phenotypes can
bemore easily matched. However, the presence of ‘‘milder’’
mutations (in RPS6KA3 [RSK2, MIM 300075] or ARX [MIM
300382], for instance) and/or incomplete penetrance of
specific clinical signs in some individuals carrying muta-
tions in genes associated with syndromic ID can blur the
distinction between syndromic and nonsyndromic ID.11
Various approaches have been developed for the identi-
fication of genes and associated causative mutations
responsible for XLID (see Lubs et al.4 for a review): (1) po-
sitional cloning based on chromosomal rearrangements or
copy-number variants (CNVs) affecting the X chromo-
some, (2) screening of genes located in candidate intervals
identified via linkage analysis in large XLID-affected fam-
ilies, (3) direct sequencing of candidate genes with a func-
tion or expression pattern that suggests a role in cognition
or that fits with metabolic or clinical observations in
affected subjects, and (4) high-throughput sequencing al-
lowing screening of mutations in all protein-coding re-
gions of the genome or only in the X chromosome (exome
versus X exome).10,12–14
The validation of potentially damaging mutations in a
gene newly associated with XLID requires functional
and/or genetic analyses, especially when the identification
is based on reportingmutations in very few families or sim-
plex cases. Functional studies are uneven in pertinence
and strength. They can include direct assessment of the
mutational impact at any of the protein, cellular, or
1Department of Translational Medicine and Neurogenetics, Institut de Ge´ne´tique et de Biologie Mole´culaire et Cellulaire, Centre National de la Recherche
Scientifique Unite´ Mixte de Recherche 7104, Institut National de la Sante´ et de la Recherche Me´dicale Unite´ 964, University of Strasbourg, 67404 Illkirch
Cedex, France; 2Chaire de Ge´ne´tique Humaine, Colle`ge de France, 75231 Paris Cedex 05, France; 3Laboratoire de Diagnostic Ge´ne´tique, Hoˆpitaux Univer-
sitaires de Strasbourg, 67091 Strasbourg Cedex, France
4These authors contributed equally to this work
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“It	  is	  perhaps	  naive	  to	  expect	  that	  these	  obstacles	  can	  be	  overcome	  
within	  the	  next	  20	  years,	  and	  it	  may	  very	  well	  be	  the	  case	  that	  there	  
might	  be	  a	  50-­‐year	  $me	  horizon	  on	  the	  secure	  implementa$on	  of	  clinical	  
genomics	  and	  individualized	  medicine.	  We	  certainly	  hope	  that	  every	  
newborn	  will	  have	  the	  vast	  majority	  of	  their	  genome	  sequenced	  and	  
digitally	  available	  by	  the	  year	  2062”.	  	  
	  
Summary	  
•  Ancestry,	  i.e.	  gene$c	  background,	  mahers.	  
•  Collec$vely,	  we	  need	  to	  improve	  the	  accuracy	  
of	  “whole”	  genomes,	  and	  also	  enable	  the	  
sharing	  of	  genotype	  and	  phenotype	  data	  
broadly,	  among	  researchers,	  the	  research	  
par$cipants	  and	  others.	  
•  We	  need	  to	  sequence	  accurate	  whole	  
genomes	  of	  large	  pedigrees,	  and	  then	  
construct	  super-­‐family	  structures.	  
	  
The	  End–	  extra	  slides	  to	  follow	  
MICROBIAL EVOLUTION
Global epistasis makes
adaptation predictable despite
sequence-level stochasticity
Sergey Kryazhimskiy,1,3*† Daniel P. Rice,1,3* Elizabeth R. Jerison,2,3 Michael M. Desai1,2,3†
Epistatic interactions between mutations can make evolutionary trajectories contingent
on the chance occurrence of initial mutations. We used experimental evolution in
Saccharomyces cerevisiae to quantify this contingency, finding differences in adaptability
among 64 closely related genotypes. Despite these differences, sequencing of 104 evolved
clones showed that initial genotype did not constrain future mutational trajectories.
Instead, reconstructed combinations of mutations revealed a pattern of diminishing-returns
epistasis: Beneficial mutations have consistently smaller effects in fitter backgrounds. Taken
together, these results show that beneficial mutations affecting a variety of biological
processes are globally coupled; they interact strongly, but only through their combined effect
on fitness. As a consequence, fitness evolution follows a predictable trajectory even though
sequence-level adaptation is stochastic.
E
pistatic interactions betweenmutations are
pervasive in microbial and viral systems
(1–6). In some cases, a single mutation can
open up previously unavailable opportuni-
ties for a population to colonize a new
metabolic niche (2) or survive in a previously
intolerable drug concentration (3). Such idio-
syncratic epistasis makes evolutionary trajecto-
ries dependent on the chance occurrence of
initial mutations that constrain or potentiate fu-
ture adaptation. This historical contingency can
render adaptation fundamentally unpredictable
(7). However, recent work has also provided evi-
dence for more systematic patterns of epistasis
(8–10), which can drive convergent phenotypic
evolution (11–13) or can lead to parallel adapta-
tion at the sequence level (14). These observa-
tions suggest that evolutionary outcomesmay be
statistically predictable ifmutations causing idio-
syncratic changes in adaptability are rare, and if
epistasis instead channels evolution into conver-
gent phenotypic or genotypic pathways.
To test how epistasis and historical contin-
gency affect the predictability of adaptation, we
conducted a hierarchical laboratory evolution
experiment in S. cerevisiae (fig. S1). In the first
phase of the experiment (“diversification”), we
created 432 independent lines from a single
haploid clone (the diversification ancestor, DivAnc)
isolated from an earlier long-term evolution ex-
periment (15).We evolved each line independently,
half at large and half at small population size, in
rich media in 96-well microplates for 240 genera-
tions (16).We then selected 64 clones (“founders”),
each from a different line, chosen to span a range
of fitness relative to the DivAnc (16) (table S1).
Founders differed from the DivAnc by 4.2 muta-
tions on average (16). In the second phase of the
experiment (“adaptation”), we founded 10 inde-
pendent replicate populations with each founder
and then allowed each of the resulting 640 lines
to adapt at large population size for 500 gen-
erations. This enabled us to compare variation
among lines descended from the same founder
(which reflects the inherent stochasticity of evo-
lution) to variation between lines descended from
different founders, thereby providing an assess-
ment of the extent to which genetic background
influences evolution.
The competitive fitness of each population
after 250 and 500 generations of the adaptation
phase increased on average by 3.3% and 6.6%,
respectively (Fig. 1A and table S2). However, not
all populations adapted at the same rate. Instead,
the initially large variation in fitness between
lines declined with time (Fig. 1A). We carried out
an analysis of variance (ANOVA) to partition ob-
served variance in fitness increase during the
adaptation phase into contributions from mea-
surement noise, inherent stochasticity of the evo-
lutionary process, and the identity of the founder
(16, 17). After 250 generations of adaptation, 49%
of the variance in fitness incrementwas attributed
to inherent evolutionary stochasticity, 17% to
measurement error, and 34% to founder iden-
tity; after 500 generations, 29% of the variance
in fitness increment was attributed to inherent
stochasticity, 21% tomeasurement error, and 50%
to founder identity (Fig. 1B and table S3). This
demonstrates that genetic background is a key
determinant of howrapidly apopulationwill adapt.
These differences in adaptability are not ran-
dom: Populations with lower initial fitness sys-
tematically adapt more rapidly than populations
with higher initial fitness, driving the overall pat-
tern of convergent evolution in fitness (Fig. 1C).
We further partitioned the variation in fitness
increment attributed to founder identity and found
that after 250 generations of adaptation, 31% of
this variation was explained by the fitness of the
founder, whereas 3% was determined by its spe-
cific genotype; for 500 generations, these percent-
ages rose to 46% and 4%, respectively (Fig. 1B
and table S3). Thus, the differences in adaptabil-
ity between founders are almost entirely predicted
by their differences in fitness and are indepen-
dent of the specific mutations underlying this
fitness. The initial fitness of the founder therefore
predicts the average rate of adaptation in its de-
scendant lines (Fig. 1D). Although the effects of
specific genotype on adaptability are rare or weak,
they are significant (fig. S2 and tables S3 and S4).
A negative correlation between fitness and
adaptability has also been observed in prokary-
otes (11, 12), and it is consistent with the common
observation in evolution experiments that the
rate of increase in fitness slows down over time
(13, 18). Combined with this earlier work, our
results suggest a general “rule of declining adap-
tability” that holds for prokaryotes and eukary-
otes adapting to rich andminimalmedia. Further,
our observations support a stronger version of
this rule: Genotypes with lower fitness are more
adaptable than those with higher fitness, and dis-
tinct genotypes with identical fitness are equally
adaptable (up to the rare or weak exceptions
noted above). This is consistentwith the argument
recently presented in (13).
The rule of declining adaptability could arise
for two non-exclusive reasons. First, there could
be only a few ways to increase in fitness. In this
model, high-fitness founders have lower adapta-
bility because they have already acquired all or
most of the possible strong-effect beneficial mu-
tations: They are “running out” of beneficial mu-
tations. In contrast, low-fitness founders adapt
more quickly because they have not yet acquired
these mutations. More generally, some groups of
mutations may have redundant functional ef-
fects (e.g., those that knock out a given pathway).
In this case, the number of nonredundant ways
to increase fitness would be much smaller than
the number of distinct beneficial mutations. We
refer to this general form of the running-out-of-
mutations hypothesis as the “modular epistasis”
model [inspired by (14)]: Each beneficial muta-
tion improves a single module, mutations within
each module are redundant, and high-fitness
founders adapt more slowly because they have
fewer remaining modules to improve, especially
among those modules that confer the largest fit-
ness gains (16).
Alternatively, mutations arising in higher-fitness
backgrounds may be less beneficial than those
arising in lower-fitness backgrounds; that is,
diminishing-returns epistasis may be pervasive
among adaptivemutations, as suggested by (8–10).
This epistasis could have two forms. If epistasis is
idiosyncratic, mutations may often have widely
different effects in different genetic backgrounds
(possibly including sign epistasis, where the sign
of the fitness effect depends on genetic back-
ground), but the average effect of a beneficial
mutation is smaller in fitter backgrounds. On the
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Sergey Kryazhimskiy,1,3*† Daniel P. Rice,1,3* Elizabeth R. Jerison,2,3 Michael M. Desai1,2,3†
Epistatic interactions between mutations can make evolutionary trajectories contingent
on the chance occurrence of initial mutations. We used experimental evolution in
Saccharomyces c revi iae to quantify this contingency, finding differences in adaptability
among 64 closely related genotypes. Despite these differences, sequencing of 104 evolved
clones showed that i itial genotype did not constrain future mutational trajectories.
Instead, reconstructed combinations of mutations revealed a pattern of diminishing-returns
epistasis: Beneficial mutations have consistently smaller effects in fitter backgrounds. Taken
together, these results show that beneficial mutations affecting a variety of biological
processes are globally coupled; they interact strongly, but only through their combined effect
on fitness. As a consequenc , fitness evolution follows a predictable trajectory even though
sequence-level d ptation is stochastic.
E
pistatic interactions betweenmutations are
pervasive in microbial and viral systems
(1–6). In some cases, a single mutation can
open up previously unavailable opportuni-
ti for a pop lation to colonize a new
metabolic niche (2) or survive in previously
intolerable drug concentration (3). Such idio-
syncratic epistasis makes evolutionary trajecto-
ries dependent on the chance occurrence of
initial mutations that constrain or potentiate fu-
ture ada tation. This historical conti gency can
render adaptation fu dament lly unpredictable
(7). How v r, recent work has also provided evi-
dence for more systematic patterns of epistasis
(8–10), which can drive convergent phenotypic
evolution (11–13) or can lead to parallel adapta-
tion at the sequence level (14). These observa-
tions suggest that evolutionary outcomesmay be
statistically p edictable ifmutat ons causing idio-
syncratic changes in adaptability are rare, and if
epistasis instead channels evolution into conver-
gent phenotypic or genotypic pathways.
To test how epistasis and historical contin-
gency affect the predictability of adaptation, we
conducted a hierarchical laboratory evolution
experiment in S. cerevisiae (fig. S1). In the first
phase of the experiment (“diversification”), we
created 432 independent lines from a si gle
haploid clone (the diversification ancestor, DivAnc)
isolated from an earlier long-term evolution ex-
periment (15).We evo ved each line independently,
half at large an half at small po ul tion size, in
rich media in 96-well microplates for 240 g ra-
tions (16).We then selected 64 clones (“founders”),
each from a different line, chosen to span range
of fitness relative to the DivAnc (16) (table S1).
Founders differed from the DivAnc by 4.2 muta-
tions on average (16). In the second phase of the
experiment (“adaptation”), we founded 10 inde-
pendent replicate populations with each founder
and then allowed each of the resulting 640 lines
to adapt at large population size for 500 gen-
erations. This enabled us to compare variation
among lines descended from the same founder
(which reflects the inherent stochasticity of evo-
lution) to variation between lines descended from
different founders, thereby providing an assess-
ment of the extent to which genetic background
influences evolution.
The competitive fitness of each population
after 250 and 500 generations of the adaptation
phase increased on average by 3.3% and 6.6%,
respectively (Fig. 1A and table S2). However, not
all populations adapted at the same rate. Instead,
the initially large variation in fitness between
lines declined with time (Fig. 1A). We carried out
an analysis of variance (ANOVA) to partition ob-
served variance in fitness increase during the
adaptation phase into contributions from mea-
surement noise, inherent stochasticity of the evo-
lutionary process, and the identity of the founder
(16, 17). After 250 generations of adaptation, 49%
of the variance in fitness incrementwas attributed
to inherent evolutionary stochasticity, 17% to
measurem t error, and 34% to founder iden-
tity; after 500 generations, 29% of the variance
in fitness increment was attributed to inherent
toch st city, 21% tomeasurement error, and 50%
to founder identity (Fig. 1B and table S3). This
demonstrates that genetic background is a key
determinant of howrapidly apopulationwill adapt.
These differences in adaptability are not ran-
dom: Populations with lower initial fitness sys-
tematically adapt more rapidly than populations
with hig er initial fitness, driving the overall pat-
tern of convergent evolution in fitness (Fig. 1C).
We further artitioned the variation in fitness
increment attributed to founder identity and found
that after 250 generations of adaptation, 31% of
this variation was explained by the fitness of the
founder, whereas 3% was determined by its spe-
cific genotype; for 500 generations, these percent-
ages rose to 46% and 4%, respectively (Fig. 1B
and table S3). Thus, the differences in adaptabil-
ity between founders are almost entirely predicted
by their differences in fitness and are indepen-
dent of the specific mutations underlying this
fitness. The initial fitness of the founder therefore
predicts the average rate of adaptation in its de-
scendant lines (Fig. 1D). Although the effects of
specific genotype on adaptability are rare or weak,
they are significant (fig. S2 and tables S3 and S4).
A negative correlation between fitness and
adaptability has also been observed in prokary-
otes (11, 12), and it is consistent with the common
observation in evolution experiments that the
rate of increase in fitness slows down over time
(13, 18). Combined with this earlier work, our
results suggest a general “rule of declining adap-
tability” that holds for prokaryotes and eukary-
otes adapting to rich andminimalmedia. Further,
our observations support a stronger version of
this rule: Genotypes with lower fitness are more
adaptable than those with higher fitness, and dis-
tinct genotypes with identical fitness are equally
adaptable (up to the rare or weak exceptions
noted above). This is consistentwith the argument
recently presented in (13).
The rule of declining adaptability could arise
for two non-exclusive reasons. First, there could
be only a few ways to increase in fitness. In this
model, high-fitness founders have lower adapta-
bility because they have already acquired all or
most of the possible strong-effect beneficial mu-
tations: They are “running out” of beneficial mu-
tations. In contrast, low-fitness founders adapt
more quickly because they have not yet acquired
these mutations. More generally, some groups of
mutations may have redundant functional ef-
fects (e.g., those that knock out a given pathway).
In this case, the number of nonredundant ways
to increase fitness would be much smaller than
the number of distinct beneficial mutations. We
refer to this general form of the running-out-of-
mutations hypothesis as the “modular epistasis”
model [inspired by (14)]: Each beneficial muta-
tion improves a single module, mutations within
each module are redundant, and high-fitness
founders adapt more slowly because they have
fewer remaining modules to improve, especially
among those modules that confer the largest fit-
ness gains (16).
Alternatively, mutations arising in higher-fitness
backgrounds may be less beneficial than those
arising in lower-fitness backgrounds; that is,
diminishing-returns epistasis may be pervasive
among adaptivemutations, as suggested by (8–10).
This epistasis could have two forms. If epistasis is
idiosyncratic, mutations may often have widely
different effects in different genetic backgrounds
(possibly including sign epistasis, where the sign
of the fitness effect depends on genetic back-
ground), but the average effect of a beneficial
mutation is smaller in fitter backgrounds. On the
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Figure S1. Experimental design. We created many independent lines from a single clone
(DivAnc) which came from a previous evolution experiment in the same environment (15) and
evolved each of them for 240 generations (Diversification). We then selected a single “Founder”
clone from 64 of these lines (chosen to span a range of fitness) and evolved 10 independent
replicate populations descended from each Founder for 500 generations (Adaptation).
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•  “Yet	  despite	  their	  lack	  of	  apparent	  func$onal	  
rela$onship,	  these	  muta$ons	  are	  globally	  
coupled	  by	  diminishing-­‐returns	  epistasis;	  their	  
eﬀects	  are	  strongly	  mediated	  by	  background	  
ﬁtness	  but	  are	  otherwise	  essen$ally	  
independent	  of	  the	  speciﬁc	  iden$ty	  of	  
muta$ons	  present	  in	  the	  background.	  The	  
biological	  basis	  of	  this	  global	  coupling	  remains	  
unknown”.	  	  
